An interventional study of Erythropoietin and Placebo in Healthy, sponsored by Morten Hostrup, PhD. Status unknown at 1 site in Denmark. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-25.
Sponsored by Morten Hostrup, PhD · Not applicable, Interventional, and Basic science
The role of exosomes in cell signalling has only recently been appreciated and is a hugely exciting and rapidly growing area, and combined with LC-MS/MS proteomics, can overcome traditional barriers to proteomics in doping applications. To our knowledge, no research has yet been undertaken to explore whether the highly promising combination of exosome proteomics has utility for rhEPO detection. The applications are extensive; the diagnostic value of differentially regulated proteins could be further validated against the existing IEF EPO WADA accredited tests using samples collected during this study, used to study altitude hypoxia versus exogenous EPO administration (WADA current targeted research 2017), investigated as a platform approach to ESA and HIF agents more generally, as well as facilitate development of direct ELISA high throughput tests.
Morten Hostrup, PhD is the lead sponsor of 14 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Saline infusion
Drug: Placebo
Erythropoetin infusion (9 IU/kg)
Drug: Erythropoietin
Erythropoetin infusion (20 IU/kg)
Drug: Erythropoietin
Subjects receive weekly infusions of EPO
Subjects receive weekly infusions of saline
Blood proteome enrichment pathway analysis in GO annotation
Change in enrichment (measured in blood and assessed using GO annotation)
Time frame: At baseline and after week 3 of treatment
Blood markers of iron
Change in blood markers of iron homeostasis
Time frame: At baseline and after week 3 of treatment
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Morten Hostrup, PhD